Latest Strategy Changes News

Page 12 of 1543
Avenira has extended its $48.9 million renounceable rights issue by more than a month as it seeks strategic and cornerstone investors. About $10.4 million has been received from investors other than major shareholder Hebang, leaving roughly $9.1 million of that allocation still available.
Victor Sage
Victor Sage
21 Sept 2026
Waterco Limited (ASX:WAT) delivered record FY26 EBIT of $23.8 million and lifted net profit after tax 59.6% to $15.4 million, despite only modest revenue growth. The stronger result supports a higher fully franked dividend, but the group is carrying more debt and inventory as it expands manufacturing capacity.
Victor Sage
Victor Sage
21 Sept 2026
X2M Connect has signed a non-binding two-year MOU with Gateway DC covering data centre development, delivery and platform deployment across Australia and potentially Southeast Asia. The opportunity links Gateway’s planned 120MW-to-2GW-plus Darwin roadmap with X2M’s prospective pipeline exceeding 200MW, but revenue remains subject to future binding agreements.
Victor Sage
Victor Sage
21 Sept 2026
Jade Gas will use targeted 2D and 3D seismic to test whether its established coal-measure gas system extends into deeper CBM, shale gas and tight sandstone horizons in Mongolia. The exploration could expand TTCBM’s longer-term potential, but the company says commercialising existing resources remains the immediate priority.
Maxwell Dee
Maxwell Dee
21 Sept 2026
VHM's refreshed feasibility study projects an A$807 million pre-tax NPV for its Goschen rare earths and mineral sands project, with approvals and major procurement work substantially advanced. The project still needs financing, lender due diligence and a Final Investment Decision before construction can begin.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Tolu Minerals has more than doubled its reported gold resources to 1.33 million ounces after declaring a maiden 293,000-ounce resource at Mt Penck in Papua New Guinea. The project also carries a largely untested copper-gold porphyry target, but its proposed A$30 million exploration program still requires separate funding.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Unith has extended its $1.5 million secured debt facility by six months and secured $320,000 of participation in its entitlement offer shortfall at a 60% premium to the latest closing price. The arrangement provides additional time to fund the business, but leaves the company with further financing costs and an undisclosed shortfall still to place.
Sophie Babbage
Sophie Babbage
21 Sept 2026
Nexus Minerals has secured firm commitments for a A$5.4 million placement to fund drilling and exploration across its Wallbrook Gold Project and NSW Mineral Project. The raise is priced below recent market benchmarks and is expected to lift cash above A$8.7 million before costs.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Larvotto Resources has produced its first gold and antimony concentrate at the Hillgrove Mine in New South Wales, moving the project from plant commissioning towards a production ramp-up. The milestone comes with binding offtake agreements already in place with Wogen Resources and Glencore International AG.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Anson Resources has signed a non-binding MoU covering a potential five-year lithium carbonate offtake with Wogen and possible project financing support from Xcelsior. The proposed supply could reach 6,000 tonnes of lithium carbonate equivalent a year, but deliveries remain dependent on Green River being financed, permitted and built.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Sunshine Metals has upgraded the economics of its Liontown project, forecasting A$179.8 million in net operating cashflow after capital over a 66-month mine life. The study points to mid-2027 mining, but depends on approvals, Mt Moss commissioning and a preliminary plan carrying a plus or minus 30% accuracy range.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
Ada Torres
21 Sept 2026

Browse the archive

Full archive